The syndrome of increased focal or generalized central nervous system (CNS) dysfunction in the early postirradiation period in patients treated with radiation therapy (RT) for malignant gliomas has not been well documented. The authors have undertaken retrospective study of 51 patients with supratentorial malignant gliomas who survived longer than 26 weeks from the time of diagnosis. All patients received irradiation and chemotherapy and were evaluated at 8-week intervals. Each evaluation consisted of a neurological examination, computerized tomography (CT) and radionuclide scans, Karnofsky rating, and an evaluation of glucocorticoid levels needed to maintain neurological function. In all, 263 evaluable periods, consisting of 1290 individual evaluable tests (parameters), were analyzed. In the first 18 weeks after RT, 26 of the 51 patients studied (51%) showed deterioration in one or more tests; 14 of the 26 (53%) did not improve. These 14 patients had a median time to tumor progression (MTP) of 31 weeks. The remaining 12 patients in this group (47%) improved and had an MTP of 73 weeks. Of the 51 patients, 25 (49%) showed deterioration significant enough to presume tumor progression (two of the following three tests were unequivocally worse: neurological examination, CT scan, and radionuclide scan), seven improved with no change in therapy and had an MTP of 66 weeks, while the other 18 had an MTP of 32 weeks. Excluding the Karnofsky rating, any individual test that showed worsening during the first 18-week period had a 33% probability of significant improvement at a subsequent evaluation period. After 18 weeks the probability of the test improving was only 4%.
T

HERAPIES for malignant primary brain tumors
include extensive tumor resection in conjunction with postoperative radiation therapy (RT). More recently, chemotherapy with oncolytic agents such as the nitrosoureas has been effective in prolonging the time to progression of tumor growth. Although most previous studies have relied on survival time as a measure of therapeutic efficacy, it now seems more appropriate to use the interval of time from diagnosis and initiation of therapy to unequivocal tumor progression in evaluating therapeutic trials.
Tumor progression can be determined with a high degree of accuracy using multiple evaluable parameters, such as the computerized tomographic (CT) scan, radionuclide (RN) scan, clinical neurological examination, steroid requirement, and Karnofsky grade. 11 When unequivocal tumor progression is documented, alternative chemotherapy or reoperation can be considered.
In the past we have changed therapy only when criteria for progression were present at the third or subsequent evaluation period (for instance, 3 months after RT), because some patients experienced postirradiation deterioration (according to some, and occasionally all, evaluable tests) that was determined on follow-up review not to be due to tumor progression. The peak period for these changes was 8 to 10 weeks after the conclusion of RT. However, changes were observed clinically as early as 1 to 2 weeks or as late as 16 weeks after irradiation. Symptoms were occasionally dramatic in onset, but more frequently were slow to appear, with clinical deterioration occurring over several days to weeks. We have held the view that major changes in therapy should not be undertaken in the 3 months immediately following irradiation, since the patient's worsening condition might be transient and attributable to RT. The exact statistical frequency of this transient deterioration, in comparison to actual tumor regrowth as a cause of early postirradiation worsening, was thought to be significant, s but had not actually been determined before this report.
Clinical Material and Methods
The clinical course of 70 successive, newly diagnosed patients with primary malignant supratentorial brain tumor, entered on a randomized Phase III protocol, were reviewed retrospectively. The protocol consisted of two arms, both of which prescribed BCNU (1,3-bis (2-chloroethyl)-l-nitrosourea), 80 mg/ sq m intravenously three times daily, and megavoltage radiation therapy, 5000 rads to the whole brain and an additional 1000 rads to a reduced field. Patients in one arm also received hydroxyurea, 275 mg/sq m orally every 6 hours on every other day, concomitantly with RT. Throughout the analysis of various factors affecting prognosis, the proportion of patients who received hydroxyurea remained relatively constant. All patients were randomized into this study within 28 days of clinical diagnosis or surgery. Histopathology on all operated cases was reviewed by a neuropathologist, Dr. Richard Davis.
Upon admission to the study, all patients underwent a baseline neurological examination, CT scan with and without contrast enhancement, and an RN scan. The CT scans were made on the EMI Head Scanner, EMI Body Scanner, or General Electric Body Scanner.* A 160 • 160 matrix was used in all cases. Patients were irradiated at doses of 170 to 180 rads/ day for a total brain dose of 5000 rads and a tumor dose of 6000 rads. The patients returned for reevaluation and BCNU therapy I to 2 weeks after their last radiation treatment, and at 8-week intervals thereafter.
Criteria for determining tumor progression in patients undergoing radiation therapy or chemotherapy have been established previously. 11 In summary, patients were evaluated before each course of chemotherapy (at 7-to 9-week intervals) by a neurological examination, contrast-enhanced CT scan, and an RN brain scan. Relative to the previous evaluation period, each test was given a score on a scale of -3 to +3. A score of 0 was assigned to baseline status when a patient entered the study, and thereafter a score of 0 indicated that there was no change in the test result during the interval since the last examination. A score of -2 or -3 indicated that there was an unequivocal increase, and a score of +2 to +3 that there was an unequivocal decrease, in one of the following: the neurological deficit, the permeability defect on the radionuclide scan, the extent of enhancement on CT scan, or the requirement for glucocorticoids. Scores of -1 and + 1 were reserved for those parameters in which either tumor progression or regression was suspected, but evidence was less than unequivocal.
Tumor progression or deterioration during therapy was defined as a score of -2 or -3 on any two of the three tests (neurological examination, enhanced CT scan, or RN scan) at the time of any evaluation after initiation of therapy.
Of the 70 patients initially included in the series, four patients withdrew from treatment or were protocol violators, four patients died of unrelated medical problems, and one patient, who was thought to have a necrotic glioblastoma at operation, was found at postmortem examination to have a cerebral metastasis from a pancreatic carcinoma. Ten patients either died early in the course of therapy or were removed from the protocol because of severely compromised neurological function that we believed to contraindicate further therapy. The remaining 51 patients, each of whom had a time to progression of longer than 26 weeks, constitute the study group of this report.
Results
The three evaluation periods immediately after completion of radiation therapy form the basis of this study. Table 1 summarizes the data accumulated for patients with at least one -2 score on clinical examination, RN scan, CT scan, or steroid dosage during one of these three evaluation periods, and their subsequent status in terms of median time to tumor progression (MTP). All 51 patients were available for the two evaluation periods immediately after radiation treatment, and 46 patients were available for the third evaluation period. It is apparent from Table 1 that patients with no -2 score, or with a -2 score that subsequently improved to a +2 score within the next 16 weeks, did better in terms of MTP than those patients with a -2 score who did not show later improvement. By the Gehan analysis 7 the former patients did twice as well as the latter (p = 0.001). Table 2 summarizes the -2 scores, by tests, for each evaluable period in patients who subsequently improved (-2 scores to +2 scores) over the next 16 weeks of evaluation. Twenty-two (42%) of the 52 parameters that were interpreted as a -2 at the first evaluation period subsequently improved to +2, and 28 (54%) of the 52 scores that were -2 at the second evaluation showed subsequent improvement. During the first evaluation period the majority of patients manifested improvement by a decreased need for glucocorticoids. During the second evaluation more patients improved clinically, and during the third evaluation period the major improvement was in the RN scan. Table 3 summarizes the relationship of type of operation to the incidence of -2 scores 26 weeks after the completion of radiation therapy. A subtotal resection of the tumor with tumor debulking and internal decompression was performed in 63% of patients; 23% had biopsy only; and 14% were not operated on. Patients who did not undergo surgery were likely to show a score of -2 on both the first and second evaluations (57%). In general, a higher percentage of the patients who were not operated on showed -2 scores or no improvement. Table 4 summarizes results for those patients who met the criterion for tumor progression (two -2 test scores) during any of the three evaluation periods. Those patients who showed subsequent improvement were compared to those who did not improve. During the first, second, and third evaluations, 20% of the patients met this criterion of deterioration. At any one of the evaluation periods, 20% of patients who had deteriorated in the preceding 8 weeks subsequently went on to improve (+2) over the next 16 weeks. Three patients (6%) met the criterion for deterioration at the second and third evaluation periods, with only one (2%) showing improvement. All together during those three evaluation periods 49% (25/51) of the patients met the criterion for tumor progression, and 28% (7/25) of this group subsequently improved. The MTP for this group was 66 weeks, in contrast to 32 weeks for those patients who fulfilled the criterion for deterioration at one of the first three evaluation periods but did not improve thereafter.
Discussion
The bleak prognosis for patients with primary supratentorial malignant gliomas has only recently become more favorable. With multimodality treatment that may include aggressive surgery, megavoltage radiation therapy of 6000 rads, and the recent addition of chemotherapy, the prolongation of life has been increased significantly in comparison to the natural history of these untreated tumors. ',5 It has become apparent that in the current treatment of cancer patients, the end point of therapeutic trials should not be survival time, but rather the time to unequivocal progression of tumor, so that alternative treatment regimens can be initiated to further prolong life. Time to progression is frequently a long interval that would permit consideration of reoperation, as well as alternative chemotherapeutic and/or radiotherapeutic regimens.
If one compares the number of -2 (unequivocal worsening) evaluable parameters on the first and second evaluation that in the subsequent 16 weeks change to a +2 (unequivocal improvement), to the number of -2 parameters in any other evaluable period that do not change to a +2, a significant difference between the groups emerges in terms of time to tumor progression. A -2 score early, in the first three evaluable periods, had a much greater chance of changing to a +2 rating in the subsequent 16 weeks than did a -2 score occurring at later evaluations.
Of the 51 patients in the study group during the first through third evaluable periods, 25 (49%) patients fulfilled the criterion for deterioration (progression of tumor). Of this group, seven (28%) patients showed improvement in the same evaluable parameters during the next 16 weeks. These patients had an MTP that was more than twice that for the remaining 18 (72%) patients who did not improve (66 versus 32 weeks). These 18 patients had tumor progression early and might have benefited from a change to alternative oncolytic agents or possible reoperation. However, if the seven patients who improved and had only transient worsening had been removed from the study group and given alternative chemotherapy and/or reopera- *Patient continues in the study without tumor progression. tEight patients had two evaluations in the first three evaluable periods with criteria of deterioration, leaving 25 of 51 patients that met criteria of deterioration in the first three periods. tion, the results would have been misleading since the alternative treatment was unnecessary.
There are several possible explanations for the transient worsening in a patient's condition 6 to 12 weeks after completion of RT. Necrotic tumor debris and other products of cell lysis are not rapidly removed from the central nervous system (CNS). The persistence of the toxic products could stimulate surrounding edema and cause permeability defects or demyelination that, theoretically, would make a patient appear worse as judged by clinical examination, CT, or RN scan.
Another contributing factor could be the delayed appearance of the direct effects of radiation; late effects of ionizing radiation on the CNS have been recognized for many years. The vascular and parenchymal changes associated with such irreversible damage and their appearance after periods ranging from 6 months to many years after radiation therapy are well documented.
There is ample evidence confirming the existence of marked alterations in brain parenchyma, varying from changes in electroencephalographic patterns to actual cytological and structural changes. 1,2,13 This transient dysfunction has been attributed to the effects of radiation on myelination. Since the latent period of the clinical onset of symptoms or changes in RN and CT scans correlates with the turnover time of myelin, believed to be 5 weeks to 2 months or more, TM it is possible that the short-term postirradiation deteriora-tion is a result ofdemyelination secondary to transient depression of enzyme systems essential to its production and maintenance) , 13 Lampert and Davis 1~ have described the histological findings obtained from a postmortem brain-stem specimen of a patient who died 12 weeks after irradiation and 1 week after the onset of bulbar symptoms. They found areas of punched-out demyelination that resembled the changes observed in. acute multiple sclerosis. The vessels showed no degenerative change. Some evidence suggests that the oligodendroglia, the myelin-producing cells, are significantly affected early in the course of treatment) , 9 Other investigators have reported the apparent clinical manifestations of this transient CNS dysfunction. Boldrey and Sheline a described eight patients with a variety of benign or malignant brain tumors who exhibited symptoms of transient brain dysfunction soon after the conclusion of RT. These patients, for the most part, had complete resolution of their symptoms with long-term survival. Freeman, et al., 6 noted a "cerebral disturbance" characterized by somnolence of varying degrees in 78% of children undergoing 2400 rads of prophylactic craniospinal RT as part of the multimodality treatment for acute lymphoblastic leukemia. Many of our patients with no other evidence of worsening exhibited minor personality changes, increased fatigue, lethargy, and prolonged sleep periods. This symptom complex appears to be a mild manifestation of the same postirradiation brain reaction.
Glucocorticoids have been administered to patients who appeared clinically worse during the postirradiation interval, in an attempt to improve neurological function. In our patients who went on to have a relatively long MTP, improvement was often prompt; in other patients, a return to levels of function that existed before the onset of deterioration was delayed for several weeks. Doses of dexamethasone as high as 40 to 60 mg/day were occasionally required to ameliorate postirradiation symptoms and signs. The group of patients who had tumor progression also improved initially with the addition of dexamethasone therapy, but their improvement was usually shortlived, with signs and symptoms of progressive neurological deficit after a brief period of improvement.
Currently, it is impossible to distinguish between the patient with tumor progression and the patient with transient postirradiation deterioration by clinical examination, CT scan, or RN scan. While reoperation would be a consideration in selected cases of suspected tumor progression, it could be unproductive, as well as potentially harmful, if deterioration reverses spontaneously. In the group of patients showing early deterioration after RT, 28% improved subsequently. Efforts to further identify this group of patients are necessary in order to justify changes in therapy before the end of the 3-month postirradiation period. In the meantime, the clinician may elect to change therapy for all patients who show evidence of deterioration after RT, even though 28% of these patients will improve spontaneously.
